Subtraction Assay for Anti-EGFRvIII Antibody Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to reliably detect human anti-EGFRvIII antibodies, which are crucial for cancer diagnosis and treatment, due to high background levels of non-specific antibody binding in standard assays.
Innovation Solution
A subtraction assay method is employed, where a blood sample is contacted with a peptide immobilized on a solid support in the presence and absence of free peptide, allowing for the calculation of specific antibody levels by subtracting non-specific binding, thereby accurately measuring EGFRvIII-specific antibodies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If a standard ELISA assay is used to detect anti-EGFRvIII antibodies, then the detection process is simple and quick, but the background levels of non-specific antibody binding are high, leading to false positives and unreliable results
Solution Approach 1:
The assay is divided into two separate portions: a first portion used to measure non-specific binding in the presence of free peptide, and a second portion used to measure total binding in the absence of free peptide. This segmentation allows for the subtraction of non-specific background from total binding, thereby isolating the specific antibody signal and improving measurement precision while maintaining the simplicity of the ELISA format
Solution Approach 2:
Free peptide acts as an intermediary substance that competes with the immobilized peptide for antibody binding. By adding excess free peptide to the first portion of the sample, non-specific binders are saturated and prevented from binding to the immobilized peptide, allowing their signal to be separately measured and subtracted from the total signal
2Reliability
If a competition-based assay is used to detect EGFR mutant protein, then the assay can detect the mutant protein, but it cannot directly indicate the presence of antibodies directed against EGFRvIII
Solution Approach 1:
The assay dynamically adjusts the binding conditions by varying the presence or absence of free peptide across different portions of the sample. This dynamic approach allows the same basic ELISA platform to serve multiple functions: detecting both mutant protein levels and antibody responses, thereby increasing versatility without sacrificing the reliability of mutant protein detection
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach effectively reduces false positives and provides accurate detection of human anti-EGFRvIII antibodies, enabling reliable cancer diagnosis and monitoring of immune responses to EGFRvIII-derived peptide vaccines.
Implementation Method 1
A first portion of a blood sample is contacted with a peptide, which is immobilized to a solid support. The peptide comprises at least 4 contiguous amino acids of SEQ ID NO: 1, including position 6 of SEQ ID NO: 1.
Implementation Method 2
The contacting is performed in the presence of the free form of the peptide. A first amount of antibody is determined from the first portion of the blood sample that bound to the peptide immobilized to the solid support.
Data Source
AI summary
Detection of human antibodies directed against the tumor-specific protein Epidermal Growth Factor Receptor variant Class III (EGFRvIII) provide information on tumor burden and vaccine response. The methods of the invention permit the specific identification of antibodies that are able to bind to EGFRvIII. The methods are useful in determining the presence of an EGFRvIII-expressing tumor and in detecting immune responses following immunization with EGFRvIII-derived peptide as part of a cancer immunotherapy regimen.